Skip to main content
. Author manuscript; available in PMC: 2022 Jan 17.
Published in final edited form as: Leukemia. 2021 Jul 17;35(10):2854–2861. doi: 10.1038/s41375-021-01342-x

Figure 5: Progression-free survival from date of off-treatment for AE.

Figure 5:

Kaplan-Meier curves are shown for 18 patients who discontinued treatment with bendamustine plus rituximab (BR) for AE and 52 patients who discontinued treatment with ibrutinib regimens (IBR) for AE (a), and Kaplan-Meier curves for 24 patients who received less 1 year (yr) of IBR and discontinued treatment for AE versus 28 patients who received more than 1 yr of IBR and discontinued treatment for AE (b). Differences in curves were tested using two-sided log-rank tests.